Preeclampsia Diagnosis and Management

Definition and Diagnosis

• Preeclampsia is defined as new-onset hypertension that develops at or after 20 weeks of gestation, accompanied by proteinuria or other signs of maternal organ dysfunction, and is a major cause of maternal and fetal morbidity and mortality worldwide, according to the European Heart Journal 1
• The American College of Cardiology defines preeclampsia as complicating 3-5% of pregnancies and is characterized by hypertension developing after 20 weeks of gestation 1
• Diagnostic criteria include blood pressure ≥140/90 mmHg, proteinuria ≥0.3 g/24 h in a 24-hour urine collection, and in the absence of proteinuria, diagnosis can be made with hypertension plus any of the following: thrombocytopenia, impaired liver function, renal insufficiency, pulmonary edema, or cerebral/visual disturbances 1

Pathophysiology

• Reduced organ perfusion affecting multiple maternal systems is a key aspect of preeclampsia, according to the European Heart Journal 1

Clinical Manifestations

• Symptoms and signs of severe preeclampsia include right upper quadrant/epigastric pain, headache, and visual disturbances due to liver edema, hepatic hemorrhage, and cerebral edema, as reported by the European Heart Journal 1
• Hyperreflexia and clonus are also symptoms of severe preeclampsia, according to the European Heart Journal 1

Risk Factors

• Important risk factors for preeclampsia include history of preeclampsia, intrauterine growth restriction, preterm birth, placental abruption, fetal death, maternal comorbid conditions, multifetal gestation, and first pregnancy, as identified by the Annals of Internal Medicine 2

Screening and Prevention

• The US Preventive Services Task Force recommends screening for preeclampsia with blood pressure measurements throughout pregnancy, as reported by the American Family Physician 3
• Low-dose aspirin is recommended to reduce the risk of preeclampsia by 24%, preterm birth by 14%, and intrauterine growth restriction by 20% in high-risk women, according to the Annals of Internal Medicine 2

Management

• The only definitive treatment for preeclampsia is delivery of the placenta and fetus, as stated by the European Heart Journal 1
• Medical management aims to control blood pressure with antihypertensive medications and prevent seizures with magnesium sulfate, according to the European Heart Journal 4

Long-term Implications

• Women with a history of preeclampsia have increased lifetime risks of cardiovascular disease, stroke, diabetes mellitus, venous thromboembolic disease, and chronic kidney disease, as reported by the Praxis Medical Insights 5

Pathophysiology of Preeclampsia

Introduction to Preeclampsia

• Preeclampsia is a multisystem disorder resulting from abnormal placentation that triggers a cascade of maternal endothelial dysfunction through angiogenic imbalance, immune dysregulation, and oxidative stress, according to the American College of Obstetricians and Gynecologists 6

Key Pathophysiological Mechanisms

• The pathophysiology of preeclampsia is best understood as a two-stage process: placental abnormalities (Stage 1) followed by maternal systemic response (Stage 2), as outlined by the American Heart Association 7
• Incomplete transformation of uteroplacental circulation results in high-resistance uteroplacental circulation and reduced placental perfusion, leading to placental hypoxia and ischemia, as reported by the European Society of Cardiology 8
• The placenta releases excessive soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) into maternal circulation, causing widespread endothelial dysfunction affecting multiple organ systems, according to the American College of Obstetricians and Gynecologists 6
• Autoimmune activation of the renin-angiotensin system occurs, contributing to the pathophysiology of preeclampsia, as stated by the American College of Obstetricians and Gynecologists 6
• Clinical heterogeneity is apparent, with early versus late onset, with or without severe features, symptomatic versus asymptomatic, as noted by the American College of Obstetricians and Gynecologists 6
• Blood pressure trends before 20 weeks may predict later development of preeclampsia, with women showing blunted decline or increase in systolic BP at higher risk, as reported by the American Heart Association 9
• Deficient natriuretic peptide signaling has been identified as a potential causal risk factor, with lower first-trimester NT-proBNP associated with increased preeclampsia risk, according to the American Heart Association 9

Clinical Implications of Pathophysiology

• Hepatic involvement causes elevated liver enzymes and epigastric pain, as reported by the European Society of Cardiology 8
• Cerebral edema leads to headache, visual disturbances, and seizures, as stated by the European Society of Cardiology 8
• Hemolysis occurs in severe cases (HELLP syndrome), as noted by the European Society of Cardiology 8

Pathophysiology of Preeclampsia

Placental Abnormalities

• Shallow cytotrophoblast invasion of maternal spiral arteries occurs, resulting in incomplete transformation of the uteroplacental circulation, according to the American Heart Association 10, 11
• The inadequate spiral artery remodeling leads to placental hypoxia and ischemia, which becomes the critical trigger for subsequent maternal syndrome, as stated by the American Society of Hypertension 12
• Placental oxidative stress increases as a consequence of reduced placental blood flow, contributing to the development of preeclampsia, as reported by the American Society of Hypertension 13, 12

Systemic Endothelial Dysfunction

• The angiogenic imbalance leads to widespread endothelial dysfunction affecting multiple organ systems, including the kidneys, liver, and brain, according to the American Society of Hypertension 12
• VEGF normally promotes vasodilation by increasing nitric oxide and prostacyclin production; sFlt-1 antagonism reduces these vasodilators, leading to endothelial dysfunction, as stated by the American Heart Association 10, 11
• Glomerular endotheliosis develops, causing proteinuria, and decreased glomerular filtration rate occurs before and at diagnosis, as reported by the American Society of Hypertension 12, 13

Renin-Angiotensin-Aldosterone System (RAAS) Dysregulation

• Circulating AT1 receptor autoantibodies are present in >95% of women with preeclampsia and correlate with disease severity, according to the American Society of Hypertension 13, 12
• These antibodies bind to a specific epitope on the second extracellular loop of the AT1 receptor, inducing vasoconstriction, hypertension, and increased coagulation, as stated by the American Society of Hypertension 13, 12

Genetic and Familial Factors

• A family history of preeclampsia conveys a relative risk of 2.9 for developing the condition, and having 2 or more first-degree relatives with cardiovascular risk factors doubles preeclampsia risk, as reported by the American Heart Association 10, 11
• Having 2 or more first-degree relatives with heart disease or stroke confers a 3-fold risk, suggesting genetic factors common to both preeclampsia and atherosclerotic disease, according to the American Heart Association 10, 11

Clinical Heterogeneity

• Preeclampsia is not a single disorder but rather different pathways converging on a common syndromic endpoint, as stated by the American Society of Hypertension 14
• Early-onset preeclampsia (before 34 weeks) is typically associated with abnormal placentation and more severe maternal and fetal outcomes, according to the American Society of Hypertension 14

Long-term Cardiovascular Implications

• The endothelial dysfunction and vascular changes suggest parallels between preeclampsia and atherosclerosis, as reported by the American Heart Association 10, 11
• Women with preeclampsia have approximately 75% increased risk of cardiovascular-related mortality compared with those without preeclampsia history, and changes in vascular biology associated with preeclampsia may account for increased risk for ischemic stroke after childbearing years, according to the American Heart Association 10, 11

Preeclampsia Pathophysiology and Clinical Implications

Introduction to Preeclampsia

• The American College of Cardiology acknowledges that inadequate blood flow to the placenta creates placental hypoxia and ischemia, which becomes the critical trigger for the subsequent maternal syndrome, with implantation defects also occurring in intrauterine growth restriction and one-third of spontaneous preterm births 15

Stage 2: Maternal Systemic Response

• The American Heart Association recognizes that the stressed, hypoxic placenta releases pathogenic factors into maternal circulation, including excess soluble Flt-1 (sFlt-1), which acts as a decoy receptor, antagonizing vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), creating a deficiency of these pro-angiogenic factors, leading to generalized endothelial dysfunction affecting multiple organ systems 16
• Glomeruloendotheliosis is the pathognomonic renal lesion, consisting of glomerular enlargement caused by hypertrophy of endothelial cells—a change seen in no other form of hypertension, with markers of endothelial activation appearing in circulation weeks to months before clinically evident disease 15, 16

Hemodynamic and Coagulation Changes

• The American College of Obstetricians and Gynecologists notes that increased sensitivity to virtually all circulating pressor agents causes vasoconstriction, though endogenous pressor levels are not elevated, with activation of the coagulation cascade occurring in most preeclamptic women, and reduced plasma volume developing due to accelerated loss of protein from the vascular compartment 15, 16

Multi-Organ Manifestations

• Hepatic involvement is characterized by reduced perfusion, causing necrosis and hemorrhage, manifesting as elevated liver enzymes and right upper quadrant/epigastric pain 16
• Cardiac involvement can lead to subendocardial necrosis, similar to hypovolemic shock, with renal involvement causing glomerular endotheliosis, proteinuria, and decreased glomerular filtration rate 15, 16

Oxidative Stress Hypothesis

• The American Heart Association proposes that oxidative stress has been proposed as the linkage between the two stages of preeclampsia, with hypoxia at the fetal-maternal interface generating free radicals that lead to oxidative stress, depending on maternal constitution, and abundant evidence of oxidative stress exists in blood and tissues of preeclamptic women 17

Maternal-Fetal Interaction and Risk Factors

• Reduced placental perfusion must interact with maternal factors to produce the maternal syndrome, including thrombophilias, with maternal risk factors that predispose to preeclampsia, such as collagen vascular disease, and insulin resistance 15, 16, 17

Relation to Long-Term Cardiovascular Disease

• The American College of Cardiology recognizes that women with preeclampsia have approximately 75% increased risk of cardiovascular-related mortality compared with those without preeclampsia history, with shared risk factors and pathophysiological mechanisms suggesting that preeclampsia may be a stress test revealing underlying cardiovascular vulnerability 15, 16

Myocardial Infarction in Postpartum Patients with Preeclampsia History

Pathophysiology and Risk Factors

• Postpartum myocardial infarction in women with preeclampsia history results primarily from accelerated atherosclerosis and persistent endothelial dysfunction, with preeclampsia conferring a 2.5-fold increased risk of coronary artery disease through shared pathophysiologic mechanisms including systemic inflammation, oxidative stress, and microvascular injury that persist long after delivery 18, 19
• Women with preeclampsia history have significantly higher prevalence of coronary atherosclerosis (36.3% vs. 28.3% in controls) and stenosis >50% (OR 2.21, 95% CI 1.42-3.44), indicating accelerated plaque formation that begins during or shortly after the affected pregnancy 18
• Coronary artery calcium scores are elevated in women with prior hypertensive disorders of pregnancy, with prevalence ratios of 1.81 for CAC >100 in preeclampsia and 2.74 in gestational hypertension, demonstrating subclinical atherosclerotic burden 18

Risk Amplification Factors

• Recurrent preeclampsia dramatically escalates MI risk, with women experiencing repeat episodes having 3-fold higher rates of MI (HR 2.90-3.19) compared to those without preeclampsia history, representing the highest-risk subgroup requiring aggressive monitoring 20, 21
• Severe preeclampsia confers greater cardiovascular risk (OR 2.74, 95% CI 2.48-3.04) compared to moderate preeclampsia (OR 2.24, 95% CI 1.72-2.93), with severity correlating directly with future MI incidence 22

Long-Term Cardiovascular Risk Profile

• Preeclampsia associates with approximately 75% increased risk of cardiovascular-related mortality (OR 1.75, 95% CI 1.46-2.06) and 2.5-fold increased risk of coronary heart disease (RR 2.50, 95% CI 1.43-4.37) compared to women without preeclampsia history 22
• The American Heart Association recommends that women with a history of preeclampsia be recognized as a high-risk group for cardiovascular disease, prompting referral to preventive cardiology screening and intensive lifestyle counseling 20

Clinical Implications

• The American College of Cardiology recommends that women with hypertensive disorders of pregnancy receive postpartum follow-up with a continuity clinician, representing a critical gap in preventive care when early intervention could mitigate long-term MI risk 20
• Preeclampsia should be recognized as a cardiovascular disease risk enhancer, prompting consideration of statin therapy when benefits outweigh risks, according to the American Heart Association 20

Preeclampsia Diagnosis and Treatment

Biomarkers and Therapeutic Targets

• The Society for Maternal-Fetal Medicine and Preeclampsia Foundation recognize that biomarkers including sFlt-1 have been investigated for their ability to predict both early- and late-onset preeclampsia, with the sFlt-1/PlGF ratio serving as a validated biomarker for preeclampsia diagnosis and risk stratification 23, 24, 25
• Dextran sulfate apheresis can reduce circulating sFlt-1 levels in early preterm preeclampsia, with pilot studies showing reduced proteinuria and stabilized blood pressure without major adverse consequences, although results require cautious interpretation as this strategy has not been evaluated through larger randomized controlled trials 23, 24, 25

Clinical Utility

• The sFlt-1/PlGF ratio can help rule out preeclampsia requiring delivery within 7-14 days in suspected cases between 20-34+6 weeks gestation, with a ratio ≥85 demonstrating 74% sensitivity and 97% specificity for predicting adverse outcomes in early-onset preeclampsia 23, 24, 25

Pathophysiology of Preeclampsia

Introduction to Angiogenic Imbalance

• Abnormal placentation with shallow cytotrophoblast invasion and defective spiral artery remodeling leads to placental ischemia and hypoxia, which is associated with the release of anti-angiogenic factors, according to the American Heart Association 26
• The stressed placenta releases pathogenic factors into maternal circulation, triggering systemic endothelial dysfunction, as stated by the American College of Obstetricians and Gynecologists 26

Role of Soluble fms-like Tyrosine Kinase-1 (sFlt-1)

• sFlt-1 is the primary anti-angiogenic mediator in preeclampsia, acting as a decoy receptor that binds and neutralizes free VEGF and PlGF in maternal circulation, as reported by the American Heart Association 27, 26
• AT1 receptor autoantibodies induce placental sFlt-1 production through AT1R activation, which is a key factor in the development of preeclampsia, according to the American College of Cardiology 27, 26

Vascular Endothelial Growth Factor (VEGF) and Endothelial Dysfunction

• VEGF deficiency is central to endothelial dysfunction, as it normally promotes vasodilation by increasing nitric oxide and prostacyclin production, as stated by the American Heart Association 27
• The loss of VEGF signaling contributes to glomerular endotheliosis, proteinuria, and decreased glomerular filtration rate, which are common complications of preeclampsia, according to the National Kidney Foundation 27

Clinical Implications of the Angiogenic Imbalance

• The combined effect of these factors produces multi-organ maternal dysfunction, including cardiovascular, renal, hepatic, cerebral, and hematologic complications, as reported by the American College of Obstetricians and Gynecologists 27

Long‑Term Cardiovascular Risk After Postpartum Pre‑eclampsia

Magnitude of Cardiovascular Risk

• Women who have experienced postpartum pre‑eclampsia have a 2.7‑fold higher risk of developing any cardiovascular disease compared with women without such a history; the excess risk persists for decades and can be detected as early as 7–10 years after delivery. 28, 29
• Overall cardiovascular‑disease mortality is ≈ 75 % higher (OR 1.73; 95 % CI 1.46‑2.06) in women with a prior postpartum pre‑eclampsia episode versus those with uncomplicated pregnancies. 28, 30

Risk Stratification by Severity

• Moderate pre‑eclampsia confers a 2.24‑fold increase in cardiovascular disease risk (OR 2.24; 95 % CI 1.72‑2.93) compared with women without pre‑eclampsia. 28, 30
• Severe pre‑eclampsia raises cardiovascular disease risk 2.74‑fold (OR 2.74; 95 % CI 2.48‑3.04) relative to uncomplicated pregnancies. 28, 30

Guideline‑Recommended Postpartum Management (International Society for the Study of Hypertension in Pregnancy, 2018)

• A mandatory 3‑month postpartum visit is required to confirm normalization of blood pressure, urinalysis, and laboratory parameters; persistent hypertension or proteinuria should trigger specialist referral. 31
• Annual lifelong follow‑up is advised for all women with chronic hypertension, gestational hypertension, or a history of pre‑eclampsia. 31
• Women should return to their pre‑pregnancy weight by 12 months postpartum and avoid excess inter‑pregnancy weight gain through lifestyle counseling. 31
• A healthy lifestyle (regular aerobic exercise, balanced diet, and attainment of ideal body weight) is recommended to mitigate long‑term risk. 31
• Calcium supplementation (1.2–2.5 g/day) is indicated when dietary calcium intake is < 600 mg/day. 31
• Cardiovascular screening (blood pressure, lipid profile, glucose metabolism, and weight assessment) should commence at 3 months postpartum and continue annually for life. 31

Clinical Implications for Women of Reproductive Age

• A woman with a prior postpartum pre‑eclampsia episode carries a significantly elevated lifelong cardiovascular risk, necessitating aggressive modification of modifiable risk factors. 31, 28, 29

Common Pitfalls to Avoid

• Do not assume that pre‑eclampsia resolves completely after delivery; cardiovascular dysfunction can emerge within a decade.
• Standard cardiovascular risk calculators underestimate risk in this population; pre‑eclampsia must be entered as a risk‑enhancing factor.
• Do not delay cardiovascular screening—initiate targeted assessments at the 3‑month postpartum visit rather than waiting years.
• Avoid routine NSAIDs for postpartum analgesia in women with a history of pre‑eclampsia, as they may raise blood pressure. 31
• Ensure the 3‑month postpartum follow‑up is completed; it is the critical window to detect persistent hypertension or proteinuria requiring referral. 31